Evidence map›Paper›PMID 26494780›Full record

Trial reportStem cells translational medicine2015

Vascular Smooth Muscle Cells From Hypertensive Patient-Derived Induced Pluripotent Stem Cells to Advance Hypertension Pharmacogenomics.

Nikolett M Biel, Katherine E Santostefano, Bayli B DiVita, Nihal El Rouby, Santiago D Carrasquilla, Chelsey Simmons, Mahito Nakanishi, Rhonda M Cooper-DeHoff, Julie A Johnson, Naohiro Terada

Open access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Stem cells translational medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 44 citations in OpenAlex.

  1. Review
  2. Review
  3. Use of iPSC-Derived Smooth Muscle Cells to Model Physiology and Pathology.Arteriosclerosis, thrombosis, and vascular biology · 2024
    Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Nikolett M BielDepartment of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA Center for Cellular Reprogramming, University of Florida, Gainesville, Florida, USA.
Katherine E SantostefanoDepartment of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA Center for Cellular Reprogramming, University of Florida, Gainesville, Florida, USA.
Bayli B DiVitaDepartment of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA Center for Cellular Reprogramming, University of Florida, Gainesville, Florida, USA.
Nihal El RoubyDepartment of Pharmacotherapy and Translational Research, College of Pharmacy and Center for Pharmacogenomics, University of Florida, Gainesville, Florida, USA.
Santiago D CarrasquillaJ. Crayton Pruitt Family Department of Biomedical Engineering, College of Engineering, University of Florida, Gainesville, Florida, USA.
Chelsey SimmonsMechanical and Aerospace Engineering, College of Engineering, University of Florida, Gainesville, Florida, USA Division of Cardiovascular Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA.
Mahito NakanishiBiotechnology Research Institute for Drug Discovery, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, Japan.
Rhonda M Cooper-DeHoffDepartment of Pharmacotherapy and Translational Research, College of Pharmacy and Center for Pharmacogenomics, University of Florida, Gainesville, Florida, USA Division of Cardiovascular Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA.
Julie A JohnsonDepartment of Pharmacotherapy and Translational Research, College of Pharmacy and Center for Pharmacogenomics, University of Florida, Gainesville, Florida, USA Division of Cardiovascular Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA.
Naohiro TeradaDepartment of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA Center for Cellular Reprogramming, University of Florida, Gainesville, Florida, USA Nikolett.Biel@otsuka-us.com terada@pathology.ufl.edu.
University of Florida · USNational Institute of Advanced Industrial Science and Technology · JP

Funding

Using social networks to map and evaluate team science across CTSA hubsUL1TR001427 · NCATS · UNIVERSITY OF FLORIDA · PI MITCHELL, DUANE A. · 2015 to 2024
$37.2M
Pharmacogenomic Evaluation of Antihypertensive ResponsesU01GM074492 · NIGMS · UNIVERSITY OF FLORIDA · PI COOPER-DEHOFF, RHONDA M, JOHNSON, JULIE A. · 2005 to 2014
$20.7M
UF Clinical and Translational Science AwardUL1TR000064 · NCATS · UNIVERSITY OF FLORIDA · PI NELSON, DAVID R · 2012 to 2014
$12.2M
NCATS NIH HHS UL1 TR000064NCATS NIH HHS UL1 TR001427NIGMS NIH HHS U01 GM074492
6 · The paper itself

Abstract

unlabelledStudies in hypertension (HTN) pharmacogenomics seek to identify genetic sources of variable antihypertensive drug response. Genetic association studies have detected single-nucleotide polymorphisms (SNPs) that link to drug responses; however, to understand mechanisms underlying how genetic traits alter drug responses, a biological interface is needed. Patient-derived induced pluripotent stem cells (iPSCs) provide a potential source for studying otherwise inaccessible tissues that may be important to antihypertensive drug response. The present study established multiple iPSC lines from an HTN pharmacogenomics cohort. We demonstrated that established HTN iPSCs can robustly and reproducibly differentiate into functional vascular smooth muscle cells (VSMCs), a cell type most relevant to vasculature tone control. Moreover, a sensitive traction force microscopy assay demonstrated that iPSC-derived VSMCs show a quantitative contractile response on physiological stimulus of endothelin-1. Furthermore, the inflammatory chemokine tumor necrosis factor α induced a typical VSMC response in iPSC-derived VSMCs. These studies pave the way for a large research initiative to decode biological significance of identified SNPs in hypertension pharmacogenomics. SIGNIFICANCE: Treatment of hypertension remains suboptimal, and a pharmacogenomics approach seeks to identify genetic biomarkers that could be used to guide treatment decisions; however, it is important to understand the biological underpinnings of genetic associations. Mouse models do not accurately recapitulate individual patient responses based on their genetics, and hypertension-relevant cells are difficult to obtain from patients. Induced pluripotent stem cell (iPSC) technology provides a great interface to bring patient cells with their genomic data into the laboratory and to study hypertensive responses. As an initial step, the present study established an iPSC bank from patients with primary hypertension and demonstrated an effective and reproducible method of generating functional vascular smooth muscle cells.

Indexed as

Cell DifferentiationAnimalsCells, CulturedFemaleHumansHypertensionInduced Pluripotent Stem CellsMaleMiceMuscle, Smooth, VascularMyocytes, Smooth MuscleHypertensionInduced pluripotent stem cellsPersonalized medicineVascular smooth muscle cells

Identifiers

PMID26494780
PMCPMC4675511
OpenAlexW2176157215

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.